Efficacy of injectable platelet-rich fibrin in the treatment of symptomatic oral lichen planus

Oral Dis. 2023 Jul;29(5):2256-2264. doi: 10.1111/odi.14261. Epub 2022 May 30.

Abstract

Objectives: The use of autologous platelet concentrates has shown growing evidence as a promising therapy. We conducted a split-mouth study to evaluate the effectiveness of injectable platelet-rich fibrin (PRF) compared with triamcinolone acetonide (TA) in the treatment of oral lichen planus (OLP).

Materials and methods: This split-mouth randomized trial included 12 patients with symptomatic, bilateral OLP lesions. The participants were randomly allocated to receive a 1-ml intralesional PRF injection on one side of the buccal mucosa and a 0.5-ml TA injection on the counterpart side. The application was performed once a week for 4 weeks. The outcomes were measured using a visual analog scale score, REU score, and lesion areas.

Results: Both injectable TA and PRF were effective in the management of oral lichen planus. After 4 weeks of treatment, there was an average reduction in the VAS score (68.5% i-PRF, 91% TA) and an average reduction in the REU score (74% i-PRF, 91% TA). There were no statistically significant differences between the two treatment methods (p > 0.05).

Conclusions: Intralesional injection with TA showed more effectiveness than i-PRF in the management of OPL lesions. Although, i-PRF cannot be considered a first-line treatment option, it showed promising alternative therapy choice with no side effects.

Keywords: intralesional injection; lichen planus; platelet-rich fibrin; triamcinolone acetonide.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Glucocorticoids / therapeutic use
  • Humans
  • Lichen Planus, Oral* / drug therapy
  • Platelet-Rich Fibrin*
  • Triamcinolone Acetonide / adverse effects
  • Triamcinolone Acetonide / therapeutic use

Substances

  • Triamcinolone Acetonide
  • Glucocorticoids